1. ZHAW digitalcollection
  2. Life Sciences und Facility Management
  3. Publikationen
  4. Publikationen Life Sciences und Facility Management
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGaspar, Diana-
dc.contributor.authorPeixoto, Rita-
dc.contributor.authorDe Pieri, Andrea-
dc.contributor.authorStriegl, Britta-
dc.contributor.authorZeugolis, Dimitrios I.-
dc.contributor.authorRaghunath, Michael-
dc.date.accessioned2021-03-26T15:13:06Z-
dc.date.available2021-03-26T15:13:06Z-
dc.date.issued2019-06-19-
dc.identifier.issn0169-409Xde_CH
dc.identifier.issn1872-8294de_CH
dc.identifier.urihttp://hdl.handle.net/10379/15896de_CH
dc.identifier.urihttps://digitalcollection.zhaw.ch/handle/11475/22184-
dc.description.abstractThe past decades have seen significant advances in pro-angiogenic strategies based on delivery of molecules and cells for conditions such as coronary artery disease, critical limb ischemia and stroke. Currently, three major strategies are evolving. Firstly, various pharmacological agents (growth factors, interleukins, small molecules, DNA/RNA) are locally applied at the ischemic region. Secondly, preparations of living cells with considerable bandwidth of tissue origin, differentiation state and preconditioning are delivered locally, rarely systemically. Thirdly, based on the notion, that cellular effects can be attributed mostly to factors secreted in situ, the cellular secretome (conditioned media, exosomes) has come into the spotlight. We review these three strategies to achieve (neo)angiogenesis in ischemic tissue with focus on the angiogenic mechanisms they tackle, such as transcription cascades, specific signalling steps and cellular gases. We also include cancer-therapy relevant lymphangiogenesis, and shall seek to explain why there are often conflicting data between in vitro and in vivo. The lion's share of data encompassing all three approaches comes from experimental animal work and we shall highlight common technical obstacles in the delivery of therapeutic molecules, cells, and secretome. This plethora of preclinical data contrasts with a dearth of clinical studies. A lack of adequate delivery vehicles and standardised assessment of clinical outcomes might play a role here, as well as regulatory, IP, and manufacturing constraints of candidate compounds; in addition, completed clinical trials have yet to reveal a successful and efficacious strategy. As the biology of angiogenesis is understood well enough for clinical purposes, it will be a matter of time to achieve success for well-stratified patients, and most probably with a combination of compounds.de_CH
dc.language.isoende_CH
dc.publisherElsevierde_CH
dc.relation.ispartofAdvanced Drug Delivery Reviewsde_CH
dc.rightsLicence according to publishing contractde_CH
dc.subjectAngiogenesisde_CH
dc.subjectCell therapyde_CH
dc.subjectCellular gasde_CH
dc.subjectDrug deliveryde_CH
dc.subjectEndothelial cellde_CH
dc.subjectProgenitor cellde_CH
dc.subjectProlyl hydroxylasede_CH
dc.subjectSecretomede_CH
dc.subjectSmall compoundde_CH
dc.subjectVascularisationde_CH
dc.subjectAnimalde_CH
dc.subjectCytokinesde_CH
dc.subjectDrug delivery systemde_CH
dc.subjectHumande_CH
dc.subjectIntercellular signaling peptides and proteinsde_CH
dc.subjectPathologic neovascularizationde_CH
dc.subjectCell- and tissue-based therapyde_CH
dc.subject.ddc610.28: Biomedizin, Biomedizinische Technikde_CH
dc.titleLocal pharmacological induction of angiogenesis : drugs for cells and cells as drugsde_CH
dc.typeBeitrag in wissenschaftlicher Zeitschriftde_CH
dcterms.typeTextde_CH
zhaw.departementLife Sciences und Facility Managementde_CH
zhaw.organisationalunitInstitut für Chemie und Biotechnologie (ICBT)de_CH
dc.identifier.doi10.1016/j.addr.2019.06.002de_CH
dc.identifier.pmid31226398de_CH
zhaw.funding.euNode_CH
zhaw.originated.zhawYesde_CH
zhaw.pages.end154de_CH
zhaw.pages.start126de_CH
zhaw.publication.statuspublishedVersionde_CH
zhaw.volume146de_CH
zhaw.publication.reviewPeer review (Publikation)de_CH
zhaw.author.additionalNode_CH
zhaw.display.portraitYesde_CH
Appears in collections:Publikationen Life Sciences und Facility Management

Files in This Item:
There are no files associated with this item.
Show simple item record
Gaspar, D., Peixoto, R., De Pieri, A., Striegl, B., Zeugolis, D. I., & Raghunath, M. (2019). Local pharmacological induction of angiogenesis : drugs for cells and cells as drugs. Advanced Drug Delivery Reviews, 146, 126–154. https://doi.org/10.1016/j.addr.2019.06.002
Gaspar, D. et al. (2019) ‘Local pharmacological induction of angiogenesis : drugs for cells and cells as drugs’, Advanced Drug Delivery Reviews, 146, pp. 126–154. Available at: https://doi.org/10.1016/j.addr.2019.06.002.
D. Gaspar, R. Peixoto, A. De Pieri, B. Striegl, D. I. Zeugolis, and M. Raghunath, “Local pharmacological induction of angiogenesis : drugs for cells and cells as drugs,” Advanced Drug Delivery Reviews, vol. 146, pp. 126–154, Jun. 2019, doi: 10.1016/j.addr.2019.06.002.
GASPAR, Diana, Rita PEIXOTO, Andrea DE PIERI, Britta STRIEGL, Dimitrios I. ZEUGOLIS und Michael RAGHUNATH, 2019. Local pharmacological induction of angiogenesis : drugs for cells and cells as drugs. Advanced Drug Delivery Reviews [online]. 19 Juni 2019. Bd. 146, S. 126–154. DOI 10.1016/j.addr.2019.06.002. Verfügbar unter: http://hdl.handle.net/10379/15896
Gaspar, Diana, Rita Peixoto, Andrea De Pieri, Britta Striegl, Dimitrios I. Zeugolis, and Michael Raghunath. 2019. “Local Pharmacological Induction of Angiogenesis : Drugs for Cells and Cells as Drugs.” Advanced Drug Delivery Reviews 146 (June): 126–54. https://doi.org/10.1016/j.addr.2019.06.002.
Gaspar, Diana, et al. “Local Pharmacological Induction of Angiogenesis : Drugs for Cells and Cells as Drugs.” Advanced Drug Delivery Reviews, vol. 146, June 2019, pp. 126–54, https://doi.org/10.1016/j.addr.2019.06.002.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.